- Home
- ERAS vs ARDC Comparison
ERAS vs ARDC Comparison
Compare ERAS & ARDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- ARDC
- Stock Information
- Founded
- ERAS 2018
- ARDC 2012
- Country
- ERAS United States
- ARDC United States
- Employees
- ERAS N/A
- ARDC N/A
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- ARDC Investment Managers
- Sector
- ERAS Health Care
- ARDC Finance
- Exchange
- ERAS Nasdaq
- ARDC Nasdaq
- Market Cap
- ERAS 348.4M
- ARDC 336.6M
- IPO Year
- ERAS 2021
- ARDC N/A
- Fundamental
- Price
- ERAS $1.37
- ARDC $14.20
- Analyst Decision
- ERAS Strong Buy
- ARDC
- Analyst Count
- ERAS 6
- ARDC 0
- Target Price
- ERAS $4.83
- ARDC N/A
- AVG Volume (30 Days)
- ERAS 1.7M
- ARDC 115.8K
- Earning Date
- ERAS 08-11-2025
- ARDC 01-01-0001
- Dividend Yield
- ERAS N/A
- ARDC 9.84%
- EPS Growth
- ERAS N/A
- ARDC N/A
- EPS
- ERAS N/A
- ARDC N/A
- Revenue
- ERAS N/A
- ARDC N/A
- Revenue This Year
- ERAS N/A
- ARDC N/A
- Revenue Next Year
- ERAS N/A
- ARDC N/A
- P/E Ratio
- ERAS N/A
- ARDC N/A
- Revenue Growth
- ERAS N/A
- ARDC N/A
- 52 Week Low
- ERAS $1.01
- ARDC $11.56
- 52 Week High
- ERAS $3.45
- ARDC $14.30
- Technical
- Relative Strength Index (RSI)
- ERAS 46.81
- ARDC 63.05
- Support Level
- ERAS $1.31
- ARDC $14.23
- Resistance Level
- ERAS $1.59
- ARDC $14.36
- Average True Range (ATR)
- ERAS 0.13
- ARDC 0.12
- MACD
- ERAS -0.02
- ARDC -0.00
- Stochastic Oscillator
- ERAS 25.00
- ARDC 74.29
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About ARDC Ares Dynamic Credit Allocation Fund Inc.
Ares Dynamic Credit Allocation Fund Inc is a closed-ended, diversified management investment company. The fund's investment objective is to provide an attractive level of total return, through current income and, secondarily, through capital appreciation. The Fund invests in a broad, dynamically managed portfolio of senior secured loans (Senior Loans) made to companies whose debt is rated below investment grade; corporate bonds (Corporate Bonds) that are high yield issues rated below investment grade; other fixed-income instruments of a similar nature that may be represented by derivatives; and securities of collateralized loan obligations (CLOs).